vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Essex Property Trust (ESS). Click either name above to swap in a different company.
Essex Property Trust is the larger business by last-quarter revenue ($479.6M vs $284.0M, roughly 1.7× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 17.9%, a 78.5% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 5.5%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 6.0%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Essex Property Trust is a publicly traded real estate investment trust that invests in apartments in California and in the Seattle metropolitan area.
ACAD vs ESS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $479.6M |
| Net Profit | $273.6M | $85.7M |
| Gross Margin | 90.8% | 70.0% |
| Operating Margin | 6.1% | 31.7% |
| Net Margin | 96.3% | 17.9% |
| Revenue YoY | 9.4% | 5.5% |
| Net Profit YoY | 90.3% | -71.6% |
| EPS (diluted) | $1.61 | $1.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $479.6M | ||
| Q3 25 | $278.6M | $473.3M | ||
| Q2 25 | $264.6M | $469.8M | ||
| Q1 25 | $244.3M | $464.6M | ||
| Q4 24 | $259.6M | $454.5M | ||
| Q3 24 | $250.4M | $450.7M | ||
| Q2 24 | $242.0M | $442.4M | ||
| Q1 24 | $205.8M | $426.9M |
| Q4 25 | $273.6M | $85.7M | ||
| Q3 25 | $71.8M | $172.7M | ||
| Q2 25 | $26.7M | $231.5M | ||
| Q1 25 | $19.0M | $212.8M | ||
| Q4 24 | $143.7M | $301.7M | ||
| Q3 24 | $32.8M | $125.5M | ||
| Q2 24 | $33.4M | $99.0M | ||
| Q1 24 | $16.6M | $285.1M |
| Q4 25 | 90.8% | 70.0% | ||
| Q3 25 | 92.2% | 69.2% | ||
| Q2 25 | 92.2% | 70.7% | ||
| Q1 25 | 91.7% | 69.6% | ||
| Q4 24 | 91.6% | 70.0% | ||
| Q3 24 | 92.5% | 69.5% | ||
| Q2 24 | 92.5% | 70.8% | ||
| Q1 24 | 88.8% | 69.7% |
| Q4 25 | 6.1% | 31.7% | ||
| Q3 25 | 12.8% | 44.5% | ||
| Q2 25 | 12.2% | 59.5% | ||
| Q1 25 | 7.9% | 55.3% | ||
| Q4 24 | 59.1% | 67.0% | ||
| Q3 24 | 12.6% | 28.6% | ||
| Q2 24 | 12.6% | 31.1% | ||
| Q1 24 | 7.4% | 31.0% |
| Q4 25 | 96.3% | 17.9% | ||
| Q3 25 | 25.8% | 36.5% | ||
| Q2 25 | 10.1% | 49.3% | ||
| Q1 25 | 7.8% | 45.8% | ||
| Q4 24 | 55.4% | 66.4% | ||
| Q3 24 | 13.1% | 27.8% | ||
| Q2 24 | 13.8% | 22.4% | ||
| Q1 24 | 8.0% | 66.8% |
| Q4 25 | $1.61 | $1.24 | ||
| Q3 25 | $0.42 | $2.56 | ||
| Q2 25 | $0.16 | $3.44 | ||
| Q1 25 | $0.11 | $3.16 | ||
| Q4 24 | $0.86 | $4.00 | ||
| Q3 24 | $0.20 | $1.84 | ||
| Q2 24 | $0.20 | $1.45 | ||
| Q1 24 | $0.10 | $4.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $76.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $5.5B |
| Total Assets | $1.6B | $13.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $76.2M | ||
| Q3 25 | $258.0M | $66.0M | ||
| Q2 25 | $253.6M | $58.7M | ||
| Q1 25 | $217.7M | $98.7M | ||
| Q4 24 | $319.6M | $66.8M | ||
| Q3 24 | $155.1M | $71.3M | ||
| Q2 24 | $177.1M | $55.2M | ||
| Q1 24 | $204.7M | $499.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $6.4B | ||
| Q2 25 | — | $6.4B | ||
| Q1 25 | — | $6.8B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $6.4B | ||
| Q2 24 | — | $6.2B | ||
| Q1 24 | — | $6.6B |
| Q4 25 | $1.2B | $5.5B | ||
| Q3 25 | $917.3M | $5.6B | ||
| Q2 25 | $822.4M | $5.6B | ||
| Q1 25 | $765.2M | $5.6B | ||
| Q4 24 | $732.8M | $5.5B | ||
| Q3 24 | $577.2M | $5.4B | ||
| Q2 24 | $516.7M | $5.5B | ||
| Q1 24 | $464.0M | $5.5B |
| Q4 25 | $1.6B | $13.2B | ||
| Q3 25 | $1.3B | $13.2B | ||
| Q2 25 | $1.2B | $13.2B | ||
| Q1 25 | $1.1B | $13.2B | ||
| Q4 24 | $1.2B | $12.9B | ||
| Q3 24 | $976.9M | $12.6B | ||
| Q2 24 | $914.1M | $12.5B | ||
| Q1 24 | $855.1M | $12.9B |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.15× | ||
| Q2 25 | — | 1.14× | ||
| Q1 25 | — | 1.22× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.18× | ||
| Q2 24 | — | 1.13× | ||
| Q1 24 | — | 1.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $1.1B |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | 12.53× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $1.1B | ||
| Q3 25 | $74.3M | $342.6M | ||
| Q2 25 | $64.0M | $216.1M | ||
| Q1 25 | $20.3M | $281.5M | ||
| Q4 24 | $40.4M | $1.1B | ||
| Q3 24 | $63.2M | $316.2M | ||
| Q2 24 | $25.0M | $218.9M | ||
| Q1 24 | $29.1M | $314.9M |
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -0.18× | 12.53× | ||
| Q3 25 | 1.03× | 1.98× | ||
| Q2 25 | 2.40× | 0.93× | ||
| Q1 25 | 1.07× | 1.32× | ||
| Q4 24 | 0.28× | 3.54× | ||
| Q3 24 | 1.93× | 2.52× | ||
| Q2 24 | 0.75× | 2.21× | ||
| Q1 24 | 1.76× | 1.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
ESS
Segment breakdown not available.
